

Zhengyang Li

Asia Associate



zli@cooley.com

Capital Markets
Mergers and Acquisitions
Asia

+852 3758 1246

Hong Kong

Zhengyang focuses on capital markets and relevant merger & acquisitions transactions and compliance matters.

Representative matters:

Capital Markets

- **Seres** in its HK\$14.28 billion initial public offering of H shares
- **MetaLight Inc.** in its HK\$242.35 million initial public offering
- **Zenergy** in its HK\$1 billion global initial public offering
- **BrainAurora Medical Technology** in its HK\$538 million initial public offering and listing on the HKEX
- **Gracell Biotechnologies** on its private placement financing of up to \$150 million
- **ImmuneOnco Biopharmaceuticals** on its HK\$319 million global initial public offering and listing on the HKEX
- **Bitdeer Technologies Group** in its US\$1.18 billion merger with Blue Safari (SPAC) and deSPAC listing on Nasdaq
- **Laekna** in its HK\$791 million (US\$101 million) initial public offering on HKEX
- **YH Entertainment**, the largest artist management company in China, on its HK\$490 million IPO on HKEX
- **Cryofocus Medtech** in its HK\$210 million (\$27 million) initial public offering of 11,110,000 H Shares on the HKEX
- **TI Cloud**, a cloud-native customer contact solution provider, on its HK\$559.4 million (US\$71.7 million) IPO and listing on HKEX

Education

China University of Political Science and Law LLM, 2021

New York University School of Law LLM, 2020

Beijing Normal University LLB, summa cum laude, 2018

Admissions & Credentials

New York